IBEXX | Therapy Access Intelligence
FAQ
Common General Questions
What distinguishes Therapy Access from traditional Market Access?
Market Access frequently focuses on price, reimbursement, benefit assessment, and payer-relevant arguments. Therapy Access, on the other hand, concentrates on whether and under what conditions a therapy can be practically implemented by the healthcare provider.
In short: Market Access clarifies whether and under what conditions a product will be reimbursed. Therapy Access shows whether it can actually be applied in everyday clinical practice—and what is required to do so.
What is the difference between Therapy Access Screening and Therapy Access Quantification?
The Therapy Access Screening identifies and prioritizes potential provider-reality factors. It highlights where opportunities, risks, and evidence gaps lie.
The Therapy Access Quantification goes deeper: it quantifies treatment pathways, process steps, staff time, infrastructure requirements, capacity effects, and Provider Economics based on concrete center reality.
Simply put:
The screening shows what to look out for and establishes hypotheses.
The quantification shows how large the effect actually is and validates the hypotheses.
Are the analyses only relevant for launch products?
No. The analyses are relevant for both launch and post-launch situations.
Particularly for products already introduced, it can help to understand why adoption is falling short of expectations, why certain centers adopt faster or slower, or which non-clinical barriers have been underestimated until now.
Frequently Asked Questions about Therapy Access Screening
What is a Therapy Access Screening?
A Therapy Access Screening is a structured analysis that examines whether a product fits well into everyday clinical practice from the perspective of healthcare providers. In doing so, we do not only look at clinical data or market access questions, but primarily at the practical reality in clinics, centers, and treatment teams: processes, resources, capacity, patient management, and economic implications.
The goal is to make it visible early on where adoption is facilitated—and where operational or economic barriers could hinder market success.
For which situations is a Therapy Access Screening suitable?
The screening is particularly suitable when a product is newly introduced, when a new competitor enters the market, when performance falls short of expectations, or when a brand team wants to better understand why adoption occurs faster or slower in certain centers or markets.
It is also suitable when a product is clinically convincing, but it remains unclear whether it is truly simple, economically plausible, and feasible in terms of capacity in the everyday life of healthcare providers.
Which specific questions does the screening answer?
- Does the product fit into existing clinical workflows?
- What additional resources might be required?
- Are there bottlenecks in personnel, infrastructure, or capacity?
- Does patient management become simpler or more complex?
- Are there economic risks or incentives for the healthcare provider?
- Does the product have a relevant provider advantage or disadvantage compared to the current standard or main competitor?
Will my product be compared with competitors or the current standard?
Yes. An important component of the screening is the consideration against the relevant comparator or today’s treatment pathway.
Because a product must not only be usable in its own right. It is often decisive whether, from the perspective of the healthcare provider, it is simpler, more relieving, more capacity-saving, or economically more attractive than today’s alternative.
What is the result of a Therapy Access Screening?
The result is a compact Screening Report that summarizes the most important provider-reality factors in a structured manner. This typically includes:
- Product & Market Snapshot
- Therapy Access Radar
- Executive Summary
- Assessment of the six dimensions
- Notes on potential adoption barriers
- Initial hypotheses on provider advantages or risks
- Recommendations for next steps
The goal is not to replace a full process cost analysis, but to make the most important topics visible and actionable early on.
How reliable is a screening without interviews or center data?
A screening is deliberately a first, rapid analysis step. It is typically based on available sources such as the Summary of Product Characteristics (SmPC), guidelines, product profile, market context, brand team input, publicly available information, and our personal experience.
It does not provide a final quantification, but a structured hypothesis about where provider-reality factors could be relevant. If critical uncertainties become visible, a Therapy Access Quantification with center input can be performed in the next step.
What data does IBEXX require for a screening?
To start, basic information about the product, the indication, the relevant market, and the most important comparator or current treatment pathway is usually sufficient.
Existing internal materials such as the brand plan, product profile, field insights, launch assumptions, market research, or access documents are also helpful. However, the screening can also start with limited data and explicitly highlight existing evidence gaps.
What happens after the screening?
After the screening, there are typically three possible next steps:
First, the brand team can directly incorporate the findings into brand planning, launch planning, messaging, or field team preparation.
Second, critical uncertainties can be specifically deepened, for example through interviews or center-based process analysis.
Third, a Therapy Access Quantification can be performed if operational, capacity-related, or economic effects are to be reliably measured and translated into concrete provider arguments.
Frequently Asked Questions about Therapy Access Quantification
What is a Therapy Access Quantification?
A Therapy Access Quantification is an in-depth analysis that measures how a product or treatment pathway is implemented in a real-world care context. In this process, workflows, resources, staff time, infrastructure requirements, capacity effects, and economic implications are systematically modeled and quantified.
The goal is not only to know if provider-reality factors are relevant, but how large their influence actually is.
When is a Therapy Access Quantification useful?
A quantification is particularly useful when operational or economic aspects are strategically relevant—for example, in the case of complex therapies, new forms of application, capacity-intensive treatments, innovative diagnostic or monitoring requirements, or products whose benefit depends heavily on practical implementation in the center.
It is also useful when a screening highlights critical questions that cannot be reliably answered with desk research alone.
What specific results does a quantification provide?
Typical results include:
- A structured treatment flow or process map
- Quantification of staff time per role
- Resource requirements by process step
- Infrastructure and diagnostic requirements
- Capacity effects, e.g., on slots, rooms, beds, or throughput
- Economic modeling from the provider’s perspective
- Comparison with current standard or relevant comparator
- Identification of bottlenecks, relief potentials, and adoption barriers
- Concrete implications for brand planning, medical, access, and field teams
How granular is the analysis?
The granularity is aligned with the specific question. For some products, an assessment at the level of central treatment steps is sufficient. For others, a detailed modeling of individual activities is useful—for example, preparation, application, monitoring, follow-up observation, documentation, pharmacy, diagnostics, or follow-up.
The aim is not maximum complexity, but the right level of detail to make decision-relevant provider effects visible.
Are real centers or healthcare providers involved?
Yes, typically the quantification is based on input from one or more relevant centers. This can involve structured interviews, process workshops, or targeted validation discussions with specialists.
Depending on the product, different roles can be involved, for example, physicians, nursing, pharmacy, administration, diagnostics, controlling, or OR/outpatient coordination.
How many centers are required?
For a focused local quantification, a well-selected reference center can already be very valuable, especially if it realistically reflects the relevant treatment situation.
If the results are to be more generalizable, several centers or different center archetypes can be included. A broader validation can subsequently take place within the framework of Therapy Access Validation & Scale-Up.
How reliable are the results?
The results are significantly more reliable than a pure desk analysis because they are based on real processes, roles, and resource assessments. At the same time, it remains important to make the context transparent: Which center was considered? What assumptions were made? Which parameters are stable and which are sensitive?
IBEXX therefore places value on comprehensible assumptions, clear model logic, and transparent sensitivities.
Is the economic efficiency for the healthcare provider also considered?
Yes. Provider Economics is a central component of the quantification. This is not about the product price alone, but about the economic reality for the healthcare provider: reimbursement, process costs, personnel and infrastructure expenditure, budget logic, billable services, potential financial risks, and the net economic effect.
It is precisely here that relevant differences often arise between products or treatment pathways that are not sufficiently visible in traditional access models.
Can the analysis be used for external communication?
Yes, but with the correct classification. The quantification can help to make provider-relevant arguments more sound—for instance, for medical dialogue, field team preparation, internal brand story sharpening, or access discussions.
Whether and how results can be used externally depends on the data basis, approvals, local regulatory requirements, and the nature of the statements. Therefore, it should be clarified early on whether the analysis is intended primarily for internal use, for strategic planning, or also for external communication.
If all participants agree, results can also be published in a journal so that they can be referenced for communication.
Will this pass our compliance?
Yes, and for us, this is not a side issue. We work with contract structures that save you months of contract loops without taking shortcuts. The collected data is processed anonymously, and the analysis is approved by the clinic. You receive a methodology that stands up to internal review by compliance and legal. If you wish, we can present the methodological documentation in advance so that your team can review it before you decide.
How much effort does this involve for our team?
Very little. We start with a process model based on SOPs, publications, and our experience, so you don’t have to train us first. From you, we need the product profile, the planned application context, and a contact person for queries. We handle the data collection in everyday clinical practice. In the end, you receive results that you can directly incorporate into the brand plan, launch board, and management presentation.
Is the quantification a health economic model?
Not in the traditional sense. A Therapy Access Quantification is not a traditional cost-benefit analysis from a payer or societal perspective. It focuses on the perspective of the healthcare provider: Which processes must be carried out? Which resources are required? Which capacities are burdened or relieved? And how does this affect the economic situation in the care context?
It complements traditional HEOR or Market Access analyses with an operational provider perspective.